298 related articles for article (PubMed ID: 35864115)
1. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma.
Todo T; Ino Y; Ohtsu H; Shibahara J; Tanaka M
Nat Commun; 2022 Jul; 13(1):4119. PubMed ID: 35864115
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
Todo T; Ito H; Ino Y; Ohtsu H; Ota Y; Shibahara J; Tanaka M
Nat Med; 2022 Aug; 28(8):1630-1639. PubMed ID: 35864254
[TBL] [Abstract][Full Text] [Related]
3. Virotherapy: The next addition to the standard of care for glioblastoma?
Broekman MLD; Nieland L; Hoeben RC
Cancer Cell; 2022 Oct; 40(10):1089-1091. PubMed ID: 36179688
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
7. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
8. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913
[TBL] [Abstract][Full Text] [Related]
9. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
10. Teserpaturev/G47Δ: First Approval.
Frampton JE
BioDrugs; 2022 Sep; 36(5):667-672. PubMed ID: 36098872
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
14. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
[TBL] [Abstract][Full Text] [Related]
15. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
16. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
18. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
20. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
